FDA Expands Afrezza to Pediatric Diabetes - Quiz - MDSpire

FDA Expands Afrezza to Pediatric Diabetes

The decision was supported by the phase 3 INHALE-1 trial and additional long-term safety, efficacy, and exposure data.

  • By

  • Kathryn Wighton

  • May 29, 2026

  • 3 min

Share

Original Source(s)

FDA Expands Afrezza to Pediatric Diabetes

  • by Kathryn Wighton

  • May 29, 2026

Related Content

Usefulness of ultrasound in diagnosing constipation in children: a narrative review

Aggression and emotional distress in adolescents: a cross-sectional chain mediation model of internet addiction and somatization

Toward Participatory Precision Health With Co-Designed Recommendations: Systematic Review of Just-in-Time Adaptive Interventions in Adolescents and Young Adults